Novel treatments for alcoholic hepatitis.
Journal
Current opinion in gastroenterology
ISSN: 1531-7056
Titre abrégé: Curr Opin Gastroenterol
Pays: United States
ID NLM: 8506887
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
The current article aims to review the latest literature on updates in therapeutics for alcohol-associated liver disease (ALD), integration of treatment of alcohol use disorder (AUD) into the management of ALD, and the role of liver transplantation for alcoholic hepatitis. ALD has recently become the most common indication for liver transplantation due to the increasing prevalence of AUD and the paucity of therapeutic options. There is broad consensus on the importance of early identification of AUD and the incorporation of its treatment in the management of ALD. New targets for treatment of alcoholic hepatitis include the gut-liver axis, anti-inflammatory drugs, antioxidants, and drugs with hepatic regenerative potential. Fecal transplantation in particular has had favorable outcomes at 1 year. n-Acetylcysteine in addition to corticosteroids, granulocyte colony stimulating factor, and IL-22 have also shown improved short-term outcomes. A number of other therapies are being studied in clinical trials and their results are anxiously awaited. In summary, there are several promising therapeutic options under clinical investigation for the treatment of alcoholic hepatitis and ALD; however, alcohol abstinence is key. In the absence of other effective therapies, liver transplantation for ALD remains a life-saving treatment with excellent patient and graft survival.
Identifiants
pubmed: 33769374
doi: 10.1097/MOG.0000000000000725
pii: 00001574-202105000-00005
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-186Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lee BP, Vittinghoff E, Dodge JL, et al. National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern Med 2019; 179:340–348.
Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2020; 71:306–333.
Boschuetz N, Cheng S, Mei L, Loy VM. Changes in alcohol use patterns in the United States during COVID-19 pandemic. WMJ 2020; 119:171–176.
Pollard MS, Tucker JS, Green HD Jr. Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US. JAMA Netw Open 2020; 3:e2022942.
Da BL, Im GY, Schiano TD. Coronavirus disease 2019 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. Hepatology 2020; 72:1102–1108.
Rogal S, Youk A, Zhang H, et al. Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis. Hepatology 2020; 71:2080–2092.
Lucey MR, Im GY, Mellinger JL, et al. Introducing the 2019 American Association for the study of liver diseases guidance on alcohol-associated liver disease. Liver Transpl 2020; 26:14–16.
Crabb DW, Bataller R, Chalasani NP, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology 2016; 150:785–790.
Bennett K, Enki DG, Thursz M, et al. Systematic review with meta-analysis: high mortality in patients with nonsevere alcoholic hepatitis. Aliment Pharmacol Ther 2019; 50:249–257.
Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology 2017; 66:1464–1473.
Altamirano J, Lopez-Pelayo H, Michelena J, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival. Hepatology 2017; 66:1842–1853.
Khan A, Tansel A, White DL, et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. Clin Gastroenterol Hepatol 2016; 14:191–202.e1–4. Quiz e20.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol 2018; 69:154–181.
Burton R, Sheron N. Missed opportunities for intervention in alcohol-related liver disease in the UK. Lancet Gastroenterol Hepatol 2017; 2:469–471.
Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol 2019; 17:2320–2329.e12.
Im GY, Mellinger JL, Winters A, et al. Provider attitudes and practices for alcohol screening, treatment and education in patients with liver disease: a survey from the AASLD ALD SIG. Clin Gastroenterol Hepatol 2020; S1542–S3565:31439–31447.
Cotter TG, Ayoub F, King AC, et al. Practice habits, knowledge, and attitudes of hepatologists to alcohol use disorder medication: sobering gaps and opportunities. Transplant Direct 2020; 6:e603.
Dunn SH, Rogal SS, Maier MM, et al. Access to comprehensive services for advanced liver disease in the veterans health administration. Dig Dis Sci 2019; 64:3471–3479.
Louvet A, Thursz MR, Kim DJ, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo – a meta-analysis of individual data from controlled trials. Gastroenterology 2018; 155:458–468.e8.
Lieber SR, Rice JP, Lucey MR, Bataller R. Controversies in clinical trials for alcoholic hepatitis. J Hepatol 2018; 68:586–592.
Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372:1619–1628.
Ndugga N, Lightbourne TG, Javaherian K, et al. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open 2017; 7:e013620.
Szabo G, Kamath PS, Shah VH, et al. Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study. Hepatology 2019; 69:2271–2283.
Singal AK, Shah VH. Current trials and novel therapeutic targets for alcoholic hepatitis. J Hepatol 2019; 70:305–313.
Mutlu EA, Gillevet PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302:G966–G978.
Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol 2019; 70:260–272.
Kelly GS. Bovine colostrums: a review of clinical uses. Altern Med Rev 2003; 8:378–394.
Sidhu S, Goyal O, Gupta A, et al. Corticosteroids and bovine colostrum in treatment of alcoholic hepatitis ‘In Extremis’: a pilot study. J Clin Exp Hepatol 2015; 5:S19–S20.
Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol 2017; 15:600–602.
Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575:505–511.
Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360:2758–2769.
Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N -acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365:1781–1789.
Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology 2015; 149:958–970.e12.
Dubuquoy L, Louvet A, Lassailly G, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut 2015; 64:1949–1960.
Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014; 109:1417–1423.
Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012; 142:505–612.e1.
Shasthry SM, Sharma MK, Shasthry V, et al. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial. Hepatology 2019; 70:802–811.
Arab JP, Sehrawat TS, Simonetto DA, et al. An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis. Hepatology 2020; 72:441–453.
Thompson J, Jones N, Al-Khafaji A, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl 2018; 24:380–393.
Mathurin P, Lucey MR. Liver transplantation in patients with alcohol-related liver disease: current status and future directions. Lancet Gastroenterol Hepatol 2020; 5:507–514.
Cotter TG, Sandikci B, Paul S, et al. Liver transplantation for alcoholic hepatitis in the US: excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant 2020; [Online ahead of print].
German MN, Eccleston JL, Tamez DA, et al. Internet published policies regarding liver transplant eligibility and substance use in United States Transplant Centers. Hepatol Commun 2020; 4:1717–1724.
Lee BP, Mehta N, Platt L, et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology 2018; 155:422–430.e1.
Lee BP, Samur S, Dalgic OO, et al. Model to calculate harms and benefits of early vs delayed liver transplantation for patients with alcohol-associated hepatitis. Gastroenterology 2019; 157:472–480.e5.
Lee BP, Vittinghoff E, Hsu C, et al. Predicting low risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the sustained alcohol use post-liver transplant score. Hepatology 2019; 69:1477–1487.